HK Stock Market Move | COUNTRY GARDEN(02007) continues to rise by nearly 8%, expected to turn a loss into a profit by 2025, and it has been previously stated that 2026 will be the "most critical year."
Country Garden Holdings (02007) rose nearly 8% again, rising 7.81% to HK$0.345 as of the time of drafting, with a turnover of HK$1.42 billion.
Country Garden (02007)rose nearly 8%, as of press time, up 7.81% to 0.345 Hong Kong dollars, with a turnover of 1.42 billion Hong Kong dollars.
In terms of news, Country Garden recently announced a profitable outlook, with estimated profits between 1 billion and 2.2 billion for the year 2025, compared to a loss of 35.145 billion in the previous year. Based on the information available, the main reason for the turnaround from loss to profit this year is the non-cash income recorded by the group from completing debt restructuring. Excluding the impact of the earlier debt restructuring income, the group's loss was mainly due to industry pressure on the gross profit level of its development business and provisions for impairment of certain assets and property projects.
It is worth mentioning that at the monthly management meeting on March 6 of this year, Yang Huiyan clearly stated that 2026 will be the most crucial year for the company to transition from "maintaining property sales" to normal operations, with the next 3 to 5 years being a critical period for accumulation. For this important period, Yang Huiyan has a clear plan: to focus on "building core competitiveness." In terms of product and service, the company will focus on customer orientation, promote the iteration of fourth-generation residential units, implement product designs that cater to different demographic needs such as aging-in-place and pet-friendly features, and leverage the advantages of the Country Garden full industry chain to enhance product design, property services, and achieve a second growth stage for Country Garden.
Related Articles

HK Stock Market Move | JD-SW(09618) rose more than 4% in the afternoon, Jingdong opens large model JoyAI-LLM Flash.

BAO PHARMA-B(02659): The follow-up of phase III clinical trial for KJ103 in desensitization treatment for kidney transplantation has been completed.

BIOSTAR PHARM-B(02563): Expected audit reservation opinion
HK Stock Market Move | JD-SW(09618) rose more than 4% in the afternoon, Jingdong opens large model JoyAI-LLM Flash.

BAO PHARMA-B(02659): The follow-up of phase III clinical trial for KJ103 in desensitization treatment for kidney transplantation has been completed.

BIOSTAR PHARM-B(02563): Expected audit reservation opinion

RECOMMEND

Pace Of Public Fund Issuance Slows, Hong Kong Stocks Become A Primary Focus
24/03/2026

Jensen Huang In‑Depth Interview: Token Economy Surge, AI Computing’s Share Of GDP To Multiply One Hundredfold, NVIDIA’s $10 Trillion Valuation Inevitable
24/03/2026

Are U.S.‑Iran Talks Genuine? At Minimum, Wall Street Read A Clear Signal From Trump’s Five‑Minute Rally
24/03/2026


